{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:44:40Z","timestamp":1780393480409,"version":"3.54.1"},"reference-count":132,"publisher":"Elsevier","isbn-type":[{"value":"9780323992275","type":"print"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/bs.apcsb.2021.11.002","type":"book-chapter","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T16:11:43Z","timestamp":1647447103000},"page":"51-90","source":"Crossref","is-referenced-by-count":8,"title":["Immunotherapeutic approaches for HPV-caused cervical cancer"],"prefix":"10.1016","member":"78","reference":[{"issue":"17\u201319","key":"10.1016\/bs.apcsb.2021.11.002_bb0010","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1016\/S0264-410X(00)00488-6","article-title":"Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer","volume":"19","author":"Adams","year":"2001","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/bs.apcsb.2021.11.002_bb0015","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0264-410X(02)00599-6","article-title":"Dendritic cell (DC) based therapy for cervical cancer: Use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly[I]:Poly [C12U] (Ampligen\u00ae)","volume":"21","author":"Adams","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/bs.apcsb.2021.11.002_bb0020","doi-asserted-by":"crossref","first-page":"927","DOI":"10.3389\/fimmu.2020.00927","article-title":"Combination vaccination with tetanus toxoid and enhanced tumor-cell based vaccine against cervical cancer in a mouse model","volume":"11","author":"Alson","year":"2020","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.apcsb.2021.11.002_bb0025","doi-asserted-by":"crossref","first-page":"105084","DOI":"10.1016\/j.meegid.2021.105084","article-title":"Designing a therapeutic and prophylactic candidate vaccine against human papillomavirus through vaccinomics approaches","volume":"95","author":"Bagheri","year":"2021","journal-title":"Infection, Genetics and Evolution"},{"issue":"38","key":"10.1016\/bs.apcsb.2021.11.002_bb0030","doi-asserted-by":"crossref","first-page":"E5290","DOI":"10.1073\/pnas.1514418112","article-title":"Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6\/E7 peptide vaccine","volume":"112","author":"Bartkowiak","year":"2015","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/bs.apcsb.2021.11.002_bb0035","first-page":"CD013479","article-title":"Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males","volume":"11","author":"Bergman","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1016\/bs.apcsb.2021.11.002_bb0040","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1080\/10717540902757721","article-title":"The efficiency of a novel delivery system (PEI600-tat) in development of potent DNA vaccine using HPV16 E7 as a model antigen","volume":"16","author":"Bolhassani","year":"2009","journal-title":"Drug Delivery"},{"issue":"10224","key":"10.1016\/bs.apcsb.2021.11.002_bb0045","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0140-6736(20)30068-4","article-title":"Impact of HPV vaccination and cervical screening on cervical cancer elimination: A comparative modelling analysis in 78 low-income and lower-middle-income countries","volume":"395","author":"Brisson","year":"2020","journal-title":"The Lancet"},{"issue":"7","key":"10.1016\/bs.apcsb.2021.11.002_bb0050","doi-asserted-by":"crossref","first-page":"e453","DOI":"10.1016\/S2214-109X(16)30099-7","article-title":"Global estimates of human papillomavirus vaccination coverage by region and income level: A pooled analysis","volume":"4","author":"Bruni","year":"2016","journal-title":"The Lancet Global Health"},{"issue":"3\u20134","key":"10.1016\/bs.apcsb.2021.11.002_bb0055","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.vaccine.2003.07.003","article-title":"Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes","volume":"22","author":"Cassetti","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/bs.apcsb.2021.11.002_bb0060","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.pvr.2017.12.006","article-title":"Therapeutic vaccines for high-risk HPV-associated diseases","volume":"5","author":"Chabeda","year":"2018","journal-title":"Papillomavirus Research"},{"issue":"2","key":"10.1016\/bs.apcsb.2021.11.002_bb0065","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/CJI.0000000000000156","article-title":"DNA vaccine encoding HPV16 oncogenes E6 and E7 induces potent cell-mediated and humoral immunity which protects in tumor challenge and drives E7-expressing skin graft rejection","volume":"40","author":"Chandra","year":"2017","journal-title":"Journal of Immunotherapy"},{"issue":"5","key":"10.1016\/bs.apcsb.2021.11.002_bb0070","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/(SICI)1097-0215(20000601)86:5<725::AID-IJC19>3.0.CO;2-K","article-title":"Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine","volume":"86","author":"Chang","year":"2000","journal-title":"International Journal of Cancer"},{"issue":"8","key":"10.1016\/bs.apcsb.2021.11.002_bb0075","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/mt.2009.118","article-title":"Treatment with cyclooxygenase-2 inhibitors enables repeated administration of vaccinia virus for control of ovarian cancer","volume":"17","author":"Chang","year":"2009","journal-title":"Molecular Therapy"},{"issue":"3","key":"10.1016\/bs.apcsb.2021.11.002_bb0080","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1021\/mp700126c","article-title":"Induction of cytotoxic T-lymphocytes and antitumor activity by a liposomal lipopeptide vaccine","volume":"5","author":"Chen","year":"2008","journal-title":"Molecular Pharmaceutics"},{"issue":"9","key":"10.1016\/bs.apcsb.2021.11.002_bb0085","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1089\/hum.2017.197","article-title":"Therapeutic DNA vaccines for human papillomavirus and associated diseases","volume":"29","author":"Cheng","year":"2018","journal-title":"Human Gene Therapy"},{"issue":"10","key":"10.1016\/bs.apcsb.2021.11.002_bb0090","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.2217\/fon.12.125","article-title":"Dendritic cell-based vaccines: Barriers and opportunities","volume":"8","author":"Cintolo","year":"2012","journal-title":"Future Oncology"},{"issue":"2","key":"10.1016\/bs.apcsb.2021.11.002_bb0095","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ygyno.2019.12.017","article-title":"Current status of therapeutic HPV vaccines","volume":"156","author":"Clark","year":"2020","journal-title":"Gynecologic Oncology"},{"key":"10.1016\/bs.apcsb.2021.11.002_bb0100","doi-asserted-by":"crossref","first-page":"592868","DOI":"10.3389\/fcell.2020.592868","article-title":"Histone deacetylase inhibitors as therapeutic interventions on cervical cancer induced by human papillomavirus","volume":"8","author":"de Freitas","year":"2020","journal-title":"Frontiers in Cell and Development Biology"},{"issue":"11","key":"10.1016\/bs.apcsb.2021.11.002_bb0105","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: A retrospective cross-sectional worldwide study","volume":"11","author":"De Sanjose","year":"2010","journal-title":"The Lancet Oncology"},{"issue":"10","key":"10.1016\/bs.apcsb.2021.11.002_bb0110","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1089\/hum.2013.102","article-title":"Enhanced therapeutic effects conferred by an experimental DNA vaccine targeting human papillomavirus-induced tumors","volume":"24","author":"Diniz","year":"2013","journal-title":"Human Gene Therapy"},{"issue":"8","key":"10.1016\/bs.apcsb.2021.11.002_bb0115","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nature Medicine"},{"issue":"1","key":"10.1016\/bs.apcsb.2021.11.002_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13027-021-00346-7","article-title":"Co-administration of 2\u20323\u2032-cGAMP STING activator and CpG-C adjuvants with a mutated form of HPV 16 E7 protein leads to tumor growth inhibition in the mouse model","volume":"16","author":"Dorostkar","year":"2021","journal-title":"Infectious Agents and Cancer"},{"issue":"18","key":"10.1016\/bs.apcsb.2021.11.002_bb0125","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.1158\/0008-5472.CAN-18-0892","article-title":"Mucosal HPV E6\/E7 peptide vaccination in combination with immune checkpoint modulation induces regression of HPV+ oral cancers","volume":"78","author":"Dorta-Estremera","year":"2018","journal-title":"Cancer Research"},{"key":"10.1016\/bs.apcsb.2021.11.002_bb0130","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.coi.2016.05.014","article-title":"Viral vectors as vaccine platforms: From immunogenicity to impact","volume":"41","author":"Ewer","year":"2016","journal-title":"Current Opinion in Immunology"},{"issue":"1","key":"10.1016\/bs.apcsb.2021.11.002_bb0135","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/imm.13285","article-title":"Recent developments in immunotherapy of cancers caused by human papillomaviruses","volume":"163","author":"Fakhr","year":"2021","journal-title":"Immunology"},{"key":"10.1016\/bs.apcsb.2021.11.002_bb0140","first-page":"2","article-title":"HSP70 modified response against HPV based tumor","volume":"2","author":"Farzanehpour","year":"2013","journal-title":"Vectors"},{"issue":"18","key":"10.1016\/bs.apcsb.2021.11.002_bb0145","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1158\/1078-0432.CCR-20-2833","article-title":"Cervical cancer immunotherapy: Facts and hopes","volume":"27","author":"Ferrall","year":"2021","journal-title":"Clinical Cancer Research"},{"issue":"3","key":"10.1016\/bs.apcsb.2021.11.002_bb0150","doi-asserted-by":"crossref","first-page":"646","DOI":"10.3390\/cancers12030646","article-title":"The interplay between antiviral signalling and carcinogenesis in human papillomavirus infections","volume":"12","author":"Ferreira","year":"2020","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/bs.apcsb.2021.11.002_bb0155","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.nano.2011.11.006","article-title":"HPV infections: Can they be eradicated using nanotechnology?","volume":"8","author":"Foldvari","year":"2011","journal-title":"Nanomedicine: Nanotechnology, Biology, and Medicine"},{"issue":"9","key":"10.1016\/bs.apcsb.2021.11.002_bb0160","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1158\/0008-5472.CAN-19-3158","article-title":"NOX4 inhibition potentiates immunotherapy by overcoming cancer-associated fibroblast-mediated CD8 T-cell exclusion from tumors","volume":"80","author":"Ford","year":"2020","journal-title":"Cancer Research"},{"issue":"1","key":"10.1016\/bs.apcsb.2021.11.002_bb0165","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD-1 pathway in tolerance and autoimmunity","volume":"236","author":"Francisco","year":"2010","journal-title":"Immunological Reviews"},{"issue":"11","key":"10.1016\/bs.apcsb.2021.11.002_bb0170","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.3390\/cancers12113101","article-title":"Plant-derived natural compounds in genetic vaccination and therapy for HPV-associated cancers","volume":"12","author":"Franconi","year":"2020","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/bs.apcsb.2021.11.002_bb0175","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/1348-0421.12408","article-title":"Synergistic antitumor effect of a human papillomavirus DNA vaccine harboring E6E7 fusion gene and vascular endothelial growth factor receptor 2 gene","volume":"60","author":"Gao","year":"2016","journal-title":"Microbiology and Immunology"},{"issue":"1","key":"10.1016\/bs.apcsb.2021.11.002_bb0180","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.semradonc.2014.07.002","article-title":"Combination regimens of radiation therapy and therapeutic cancer vaccines: Mechanisms and opportunities","volume":"25","author":"Garnett-Benson","year":"2015","journal-title":"Seminars in Radiation Oncology"},{"issue":"36","key":"10.1016\/bs.apcsb.2021.11.002_bb0185","doi-asserted-by":"crossref","first-page":"14604","DOI":"10.1073\/pnas.1209367109","article-title":"Nonviral delivery of self-amplifying RNA vaccines","volume":"109","author":"Geall","year":"2012","journal-title":"Proceedings Natl Acad Sci USA"},{"issue":"5","key":"10.1016\/bs.apcsb.2021.11.002_bb0190","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1358\/dot.2018.54.5.2807864","article-title":"Plasmid DNA vaccines: Where are we now?","volume":"54","author":"Ghaffarifar","year":"2018","journal-title":"Drugs Today"},{"issue":"7","key":"10.1016\/bs.apcsb.2021.11.002_bb0195","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s00262-006-0247-2","article-title":"Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice","volume":"56","author":"Gomez-Gutierrez","year":"2007","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"7","key":"10.1016\/bs.apcsb.2021.11.002_bb0200","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1002\/(SICI)1097-0142(20000401)88:7<1650::AID-CNCR20>3.0.CO;2-L","article-title":"Human tumor growth is inhibited by a vaccinia virus carrying the E2 gene of bovine papillomavirus","volume":"88","author":"Graham","year":"2000","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/bs.apcsb.2021.11.002_bb0205","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1629259","article-title":"HPV16 RNA-LPX vaccine mediates complete regression of aggressively growing HPV-positive mouse tumors and establishes protective T cell memory","volume":"8","author":"Grunwitz","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/bs.apcsb.2021.11.002_bb0210","doi-asserted-by":"crossref","first-page":"8037","DOI":"10.2147\/OTT.S264312","article-title":"Cervical cancer: Emerging immune landscape and treatment","volume":"13","author":"Guo","year":"2020","journal-title":"Oncotargets and Therapy"},{"key":"10.1016\/bs.apcsb.2021.11.002_bb0215","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.bpobgyn.2017.09.008","article-title":"Therapeutic HPV vaccines","volume":"47","author":"Hancock","year":"2018","journal-title":"Best Practice & Research. Clinical Obstetrics & Gynaecology"},{"issue":"2","key":"10.1016\/bs.apcsb.2021.11.002_bb0220","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1042\/BA20000034","article-title":"Design and production of recombinant subunit vaccines","volume":"32","author":"Hansson","year":"2000","journal-title":"Biotechnology and Applied Biochemistry"},{"issue":"3","key":"10.1016\/bs.apcsb.2021.11.002_bb0225","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ijrobp.2020.02.031","article-title":"A phase 1 trial assessing the safety and tolerability of a therapeutic DNA vaccination against HPV16 and HPV18 E6\/E7 oncogenes after chemoradiation for cervical cancer","volume":"107","author":"Hasan","year":"2020","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"5","key":"10.1016\/bs.apcsb.2021.11.002_bb0230","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.3390\/jcm10051044","article-title":"RG1-VLP and other L2-based, broad-spectrum HPV vaccine candidates","volume":"10","author":"Huber","year":"2021","journal-title":"Journal of Clinical Medicine"},{"issue":"1","key":"10.1016\/bs.apcsb.2021.11.002_bb0235","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1600-065X.2008.00622.x","article-title":"Antigen-specific immunotherapy of cervical and ovarian cancer","volume":"222","author":"Hung","year":"2008","journal-title":"Immunological Reviews"},{"issue":"7","key":"10.1016\/bs.apcsb.2021.11.002_bb0240","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/gt.2015.24","article-title":"Antigen design enhances the immunogenicity of Semliki Forest virus-based therapeutic human papillomavirus vaccines","volume":"22","author":"Ip","year":"2015","journal-title":"Gene Therapy"},{"issue":"3","key":"10.1016\/bs.apcsb.2021.11.002_bb0245","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.4049\/jimmunol.1400656","article-title":"Enhancement of tumor-specific T cell-mediated immunity in dendritic cell-based vaccines by mycobacterium tuberculosis heat shock protein X","volume":"193","author":"Jung","year":"2014","journal-title":"Journal of Immunology"},{"issue":"2","key":"10.1016\/bs.apcsb.2021.11.002_bb0250","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.imlet.2006.05.004","article-title":"Enhancement of dendritic cell-based vaccine potency by targeting antigen to endosomal\/lysosomal compartments","volume":"106","author":"Kang","year":"2006","journal-title":"Immunology Letters"},{"issue":"1","key":"10.1016\/bs.apcsb.2021.11.002_bb0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-62448-3","article-title":"Combination therapy using human papillomavirus L1\/E6\/E7 genes and archaeosome: A nanovaccine confer immuneadjuvanting effects to fight cervical cancer","volume":"10","author":"Karimi","year":"2020","journal-title":"Scientific Reports"},{"key":"10.1016\/bs.apcsb.2021.11.002_bb0260","first-page":"753427","article-title":"Tumor inhibition by DepoVax-based cancer vaccine is accompanied by reduced regulatory\/suppressor cell proliferation and tumor infiltration","volume":"2013","author":"Karkada","year":"2013","journal-title":"International Scholarly Research Notices"},{"issue":"12","key":"10.1016\/bs.apcsb.2021.11.002_bb0265","first-page":"3676","article-title":"Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer","volume":"8","author":"Kaufmann","year":"2002","journal-title":"Clinical Cancer Research"},{"issue":"7","key":"10.1016\/bs.apcsb.2021.11.002_bb0270","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.3109\/10717544.2015.1019653","article-title":"Archaeosomes: An excellent carrier for drug and cell delivery","volume":"23","author":"Kaur","year":"2016","journal-title":"Drug Delivery"},{"issue":"1","key":"10.1016\/bs.apcsb.2021.11.002_bb0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-014-0229-7","article-title":"Identification of novel epitopes from human papillomavirus type 18 E7 that can sensitize PBMCs of multiple HLA class I against human cervical cancer","volume":"12","author":"Kim","year":"2014","journal-title":"Journal of Translational Medicine"},{"key":"10.1016\/bs.apcsb.2021.11.002_bb0380","series-title":"Kidney transplantation: Principles and practice","author":"Knechtle","year":"2019"},{"issue":"Suppl 14","key":"10.1016\/bs.apcsb.2021.11.002_bb0280","article-title":"Abstract LB-095: HPV E7 antigen-expressing Listeria-based immunotherapy (ADXS11-001) prior to robotic surgery for HPV-positive oropharyngeal cancer enhances HPV-specific T cell immunity","volume":"76","author":"Krupar","year":"2016","journal-title":"Cancer Research"},{"key":"10.1016\/bs.apcsb.2021.11.002_bb0285","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/978-3-030-01881-8_2","article-title":"Live-attenuated bacterial vectors for delivery of mucosal vaccines, DNA vaccines, and cancer immunotherapy","volume":"26","author":"Kumar","year":"2019","journal-title":"Pharmaceuticals from Microbes"},{"issue":"2","key":"10.1016\/bs.apcsb.2021.11.002_bb0290","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.mjafi.2015.02.006","article-title":"HPV vaccine: Current status and future directions","volume":"71","author":"Kumar","year":"2015","journal-title":"Medical Journal, Armed Forces India"},{"issue":"5","key":"10.1016\/bs.apcsb.2021.11.002_bb0295","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.3390\/cancers12051060","article-title":"HPV involvement in the tumor microenvironment and immune treatment in head and neck squamous cell carcinomas","volume":"12","author":"Lechien","year":"2020","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/bs.apcsb.2021.11.002_bb0300","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s00109-013-1054-9","article-title":"Histone deacetylase inhibitor AR-42 enhances E7-specific CD8+ T cell-mediated antitumor immunity induced by therapeutic HPV DNA vaccination","volume":"91","author":"Lee","year":"2013","journal-title":"Journal of Molecular Medicine"},{"issue":"3","key":"10.1016\/bs.apcsb.2021.11.002_bb0305","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1080\/21645515.2018.1547604","article-title":"Pleurotus ferulae polysaccharides improve the antitumor efficacy of therapeutic human papillomavirus dendritic cell-based vaccine","volume":"15","author":"Li","year":"2019","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"9","key":"10.1016\/bs.apcsb.2021.11.002_bb0310","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1002\/cam4.1143","article-title":"A combination of anti-PD-L1 mA b plus lm-LLO-E6 vaccine efficiently suppresses tumor growth and metastasis in HPV-infected cancers","volume":"6","author":"Lin","year":"2017","journal-title":"Cancer Medicine"},{"issue":"1","key":"10.1016\/bs.apcsb.2021.11.002_bb0315","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s12026-009-8141-6","article-title":"Therapeutic HPV DNA vaccines","volume":"47","author":"Lin","year":"2010","journal-title":"Immunologic Research"},{"issue":"52","key":"10.1016\/bs.apcsb.2021.11.002_bb0320","doi-asserted-by":"crossref","first-page":"7352","DOI":"10.1016\/j.vaccine.2009.09.042","article-title":"Gene gun administration of therapeutic HPV DNA vaccination restores the efficacy of prolonged defrosted viral based vaccine","volume":"27","author":"Lin","year":"2009","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/bs.apcsb.2021.11.002_bb0330","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1128\/JVI.74.6.2888-2894.2000","article-title":"Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer","volume":"74","author":"Liu","year":"2000","journal-title":"Journal of Virology"},{"key":"10.1016\/bs.apcsb.2021.11.002_bb0325","doi-asserted-by":"crossref","first-page":"6842963","DOI":"10.1155\/2020\/6842963","article-title":"Research progress on tumor-associated macrophages and inflammation in cervical cancer","volume":"2020","author":"Liu","year":"2020","journal-title":"BioMed Research International"},{"key":"10.1016\/bs.apcsb.2021.11.002_bb0335","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3389\/fphar.2019.00065","article-title":"PD-1\/PD-L1 inhibitors in cervical cancer","volume":"10","author":"Liu","year":"2019","journal-title":"Frontiers in Pharmacology"},{"issue":"6","key":"10.1016\/bs.apcsb.2021.11.002_bb0340","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1147641","article-title":"A novel dendritic cell targeting HPV16 E7 synthetic vaccine in combination with PD-L1 blockade elicits therapeutic antitumor immunity in mice","volume":"5","author":"Liu","year":"2016","journal-title":"Oncoimmunology"},{"issue":"12","key":"10.1016\/bs.apcsb.2021.11.002_bb0345","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.3390\/molecules23123310","article-title":"Self-replicating RNA viruses for RNA therapeutics","volume":"23","author":"Lundstrom","year":"2018","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/bs.apcsb.2021.11.002_bb0350","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1021\/acs.chemrev.9b00472","article-title":"Peptide-based vaccines: Current progress and future challenges","volume":"120","author":"Malonis","year":"2019","journal-title":"Chemical Reviews"},{"issue":"1","key":"10.1016\/bs.apcsb.2021.11.002_bb0355","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/jamaoncol.2018.4051","article-title":"Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16\u2013related cancer: A phase 2 clinical trial","volume":"5","author":"Massarelli","year":"2019","journal-title":"JAMA Oncology"},{"issue":"535","key":"10.1016\/bs.apcsb.2021.11.002_bb0360","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz8235","article-title":"Strong vaccine responses during chemotherapy are associated with prolonged cancer survival","volume":"12","author":"Melief","year":"2020","journal-title":"Science Translational Medicine"},{"issue":"2","key":"10.1016\/bs.apcsb.2021.11.002_bb0365","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00705-016-3091-5","article-title":"Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine","volume":"162","author":"Moeini","year":"2017","journal-title":"Archives of Virology"},{"issue":"6","key":"10.1016\/bs.apcsb.2021.11.002_bb0370","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1158\/1535-7163.MCT-14-1015","article-title":"Synergy of radiotherapy and a cancer vaccine for the treatment of HPV-associated head and neck cancer","volume":"14","author":"Mondini","year":"2015","journal-title":"Molecular Cancer Therapeutics"},{"issue":"9","key":"10.1016\/bs.apcsb.2021.11.002_bb0375","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1586\/erv.09.76","article-title":"Therapeutic HPV DNA vaccines","volume":"8","author":"Monie","year":"2009","journal-title":"Expert Review of Vaccines"},{"issue":"2","key":"10.1016\/bs.apcsb.2021.11.002_bb0385","first-page":"79","article-title":"COVID-19 vaccine global access is an urgency","volume":"46","author":"Negahdaripour","year":"2021","journal-title":"Iranian Journal of Medical Sciences"},{"key":"10.1016\/bs.apcsb.2021.11.002_bb0390","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.meegid.2017.08.002","article-title":"A novel HPV prophylactic peptide vaccine, designed by immunoinformatics and structural vaccinology approaches","volume":"54","author":"Negahdaripour","year":"2017","journal-title":"Infection, Genetics and Evolution"},{"issue":"5","key":"10.1016\/bs.apcsb.2021.11.002_bb0395","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.biotechadv.2017.05.002","article-title":"Harnessing self-assembled peptide nanoparticles in epitope vaccine design","volume":"35","author":"Negahdaripour","year":"2017","journal-title":"Biotechnology Advances"},{"key":"10.1016\/bs.apcsb.2021.11.002_bb0400","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.meegid.2017.12.008","article-title":"Structural vaccinology considerations for in silico designing of a multi-epitope vaccine","volume":"58","author":"Negahdaripour","year":"2018","journal-title":"Infection, Genetics and Evolution"},{"issue":"4","key":"10.1016\/bs.apcsb.2021.11.002_bb0405","doi-asserted-by":"crossref","first-page":"316","DOI":"10.2174\/1389201020666191114104850","article-title":"Production and preliminary in vivo evaluations of a novel in silico-designed L2-based potential HPV vaccine","volume":"21","author":"Negahdaripour","year":"2020","journal-title":"Current Pharmaceutical Biotechnology"},{"key":"10.1016\/bs.apcsb.2021.11.002_bb0410","article-title":"Administration of COVID-19 vaccines in immunocompromised patients","volume":"108021","author":"Negahdaripour","year":"2021","journal-title":"International Immunopharmacology"},{"issue":"4","key":"10.1016\/bs.apcsb.2021.11.002_bb0415","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3390\/vaccines8040568","article-title":"Progress in L2-based prophylactic vaccine development for protection against diverse human papillomavirus genotypes and associated diseases","volume":"8","author":"Olczak","year":"2020","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/bs.apcsb.2021.11.002_bb0420","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.rpor.2018.05.001","article-title":"The current status of immunotherapy for cervical cancer","volume":"23","author":"Orbegoso","year":"2018","journal-title":"Reports of Practical Oncology and Radiotherapy"},{"key":"10.1016\/bs.apcsb.2021.11.002_bb0425","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/bs.apcsb.2015.08.004","article-title":"Human papillomavirus vaccine: State of the art and future perspectives","volume":"101","author":"Panatto","year":"2015","journal-title":"Advances in Protein Chemistry and Structural Biology"},{"issue":"4","key":"10.1016\/bs.apcsb.2021.11.002_bb0430","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines-a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"9270","key":"10.1016\/bs.apcsb.2021.11.002_bb0435","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/S0140-6736(00)04904-7","article-title":"An overview of the immune system","volume":"357","author":"Parkin","year":"2001","journal-title":"The Lancet"},{"issue":"41","key":"10.1016\/bs.apcsb.2021.11.002_bb0440","doi-asserted-by":"crossref","first-page":"1700737","DOI":"10.2807\/1560-7917.ES.2018.23.41.1700737","article-title":"The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: What additional disease burden will a nonavalent vaccine prevent?","volume":"23","author":"Patel","year":"2018","journal-title":"Eurosurveillance"},{"issue":"7","key":"10.1016\/bs.apcsb.2021.11.002_bb0445","doi-asserted-by":"crossref","first-page":"e141912","DOI":"10.1172\/jci.insight.141912","article-title":"Characterization of recombinant gorilla adenovirus HPV therapeutic vaccine PRGN-2009","volume":"6","author":"Pellom","year":"2021","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/bs.apcsb.2021.11.002_bb0450","doi-asserted-by":"crossref","first-page":"e03220","DOI":"10.1128\/mBio.03224-20","article-title":"Development of DNA vaccine targeting E6 and E7 proteins of human papillomavirus 16 (HPV16) and HPV18 for immunotherapy in combination with recombinant vaccinia boost and PD-1 antibody","volume":"12","author":"Peng","year":"2021","journal-title":"MBio"},{"issue":"4","key":"10.1016\/bs.apcsb.2021.11.002_bb0455","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s00262-020-02754-x","article-title":"PD-1 blockade synergizes with intratumoral vaccination of a therapeutic HPV protein vaccine and elicits regression of tumor in a preclinical model","volume":"70","author":"Peng","year":"2021","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"1","key":"10.1016\/bs.apcsb.2021.11.002_bb0460","doi-asserted-by":"crossref","first-page":"e0004s","DOI":"10.5041\/RMMJ.10179","article-title":"Adoptive T cell immunotherapy for cancer","volume":"6","author":"Perica","year":"2015","journal-title":"Rambam Maimonides Medical Journal"},{"issue":"3","key":"10.1016\/bs.apcsb.2021.11.002_bb0465","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s12307-011-0066-7","article-title":"Immunosuppressive tumor microenvironment in cervical cancer patients","volume":"4","author":"Piersma","year":"2011","journal-title":"Cancer Microenvironment"},{"issue":"17","key":"10.1016\/bs.apcsb.2021.11.002_bb0470","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1016\/bs.apcsb.2021.11.002_bb0475","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3390\/cancers11030368","article-title":"Effect of multiple vaccinations with tumor cell-based vaccine with codon-modified GM-CSF on tumor growth in a mouse model","volume":"11","author":"Qiu","year":"2019","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/bs.apcsb.2021.11.002_bb0480","doi-asserted-by":"crossref","first-page":"1949896","DOI":"10.1080\/2162402X.2021.1949896","article-title":"A therapeutic DNA vaccine and gemcitabine act synergistically to eradicate HPV-associated tumors in a preclinical model","volume":"10","author":"Ramos da Silva","year":"2021","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/bs.apcsb.2021.11.002_bb0485","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3390\/vaccines8010111","article-title":"Development of tumor cell-based vaccine with IL-12 gene Electrotransfer as adjuvant","volume":"8","author":"Remic","year":"2020","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/bs.apcsb.2021.11.002_bb0490","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/cgt.2015.40","article-title":"An HPV-E6\/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression","volume":"22","author":"Rice","year":"2015","journal-title":"Cancer Gene Therapy"},{"issue":"1","key":"10.1016\/bs.apcsb.2021.11.002_bb0495","doi-asserted-by":"crossref","first-page":"e000612","DOI":"10.1136\/jitc-2020-000612","article-title":"Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine","volume":"8","author":"Rumfield","year":"2020","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10.1016\/bs.apcsb.2021.11.002_bb0500","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2147\/ITT.S273327","article-title":"Therapeutic vaccines for HPV-associated malignancies","volume":"9","author":"Rumfield","year":"2020","journal-title":"ImmunoTargets and Therapy"},{"issue":"1","key":"10.1016\/bs.apcsb.2021.11.002_bb0505","first-page":"608","article-title":"Combination therapies for HPV-associated malignancies","volume":"12","author":"Rumfield","year":"2021","journal-title":"Journal of Clinical & Cellular Immunology"},{"issue":"1","key":"10.1016\/bs.apcsb.2021.11.002_bb0510","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/cr.2016.157","article-title":"Dendritic cell-based immunotherapy","volume":"27","author":"Sabado","year":"2017","journal-title":"Cell Research"},{"issue":"28","key":"10.1016\/bs.apcsb.2021.11.002_bb0515","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1016\/j.vaccine.2015.05.015","article-title":"MPG-based nanoparticle: An efficient delivery system for enhancing the potency of DNA vaccine expressing HPV16E7","volume":"33","author":"Saleh","year":"2015","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/bs.apcsb.2021.11.002_bb0520","doi-asserted-by":"crossref","first-page":"443","DOI":"10.4049\/jimmunol.1701024","article-title":"Dendritic cell-based Cancer vaccines","volume":"200","author":"Santos","year":"2018","journal-title":"Journal of Immunology"},{"key":"10.1016\/bs.apcsb.2021.11.002_bb0525","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.virusres.2016.11.020","article-title":"Developments in L2-based human papillomavirus (HPV) vaccines","volume":"231","author":"Schellenbacher","year":"2017","journal-title":"Virus Research"},{"key":"10.1016\/bs.apcsb.2021.11.002_bb0530","doi-asserted-by":"crossref","first-page":"F123","DOI":"10.1016\/j.vaccine.2012.04.108","article-title":"A review of clinical trials of human papillomavirus prophylactic vaccines","volume":"30","author":"Schiller","year":"2012","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/bs.apcsb.2021.11.002_bb0535","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1086\/599988","article-title":"Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials","volume":"200","author":"Schiller","year":"2009","journal-title":"The Journal of Infectious Diseases"},{"issue":"5","key":"10.1016\/bs.apcsb.2021.11.002_bb0540","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S1470-2045(14)71179-9","article-title":"Next generation prophylactic human papillomavirus vaccines","volume":"16","author":"Schiller","year":"2015","journal-title":"The Lancet Oncology"},{"issue":"Suppl. 15","key":"10.1016\/bs.apcsb.2021.11.002_bb0545","article-title":"Live-attenuated LCMV-based vector for active immunotherapy of HPV16 + cancer","volume":"37","author":"Schmidt","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/bs.apcsb.2021.11.002_bb0550","doi-asserted-by":"crossref","first-page":"xi40-xi41","DOI":"10.1093\/annonc\/mdz451.018","article-title":"Phase I clinical study for validation of Fimaporfin-based photochemical internalisation: A novel technology for enhancing cellular immune responses important for therapeutic effect of peptide-and protein-based vaccines","volume":"30","author":"Selbo","year":"2019","journal-title":"Annals of Oncology"},{"issue":"9","key":"10.1016\/bs.apcsb.2021.11.002_bb0555","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1158\/2326-6066.CIR-17-0292","article-title":"Concurrent PD-1 blockade negates the effects of OX40 agonist antibody in combination immunotherapy through inducing T-cell apoptosis","volume":"5","author":"Shrimali","year":"2017","journal-title":"Cancer Immunology Research"},{"issue":"1","key":"10.1016\/bs.apcsb.2021.11.002_bb0560","first-page":"9","article-title":"Cancer statistics, 2012","volume":"64","author":"Siegal","year":"2014","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.1016\/bs.apcsb.2021.11.002_bb0565","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1590\/S1517-83822014000400001","article-title":"Live bacterial vaccine vectors: An overview","volume":"45","author":"Silva","year":"2014","journal-title":"Brazilian Journal of Microbiology"},{"issue":"34","key":"10.1016\/bs.apcsb.2021.11.002_bb0570","doi-asserted-by":"crossref","first-page":"54952","DOI":"10.18632\/oncotarget.10712","article-title":"Tumor growth accelerated by chemotherapy-induced senescent cells is suppressed by treatment with IL-12 producing cellular vaccines","volume":"7","author":"Simova","year":"2016","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/bs.apcsb.2021.11.002_bb0575","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1080\/21645515.2015.1136039","article-title":"Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases","volume":"12","author":"Skeate","year":"2016","journal-title":"Human Vaccines & Immunotherapeutics"},{"key":"10.1016\/bs.apcsb.2021.11.002_bb0580","doi-asserted-by":"crossref","first-page":"292951","DOI":"10.5402\/2011\/292951","article-title":"Safety and immunogenicity of a human papillomavirus peptide vaccine (CIGB-228) in women with high-grade cervical intraepithelial neoplasia: First-in-human, proof-of-concept trial","volume":"2011","author":"Solares","year":"2011","journal-title":"ISRN Obstetrics and Gynecology"},{"key":"10.1016\/bs.apcsb.2021.11.002_bb0585","doi-asserted-by":"crossref","first-page":"200212","DOI":"10.1016\/j.tvr.2021.200212","article-title":"Harnessing immunity for therapy in human papillomavirus driven cancers","volume":"11","author":"Stern","year":"2021","journal-title":"Tumour Virus Research"},{"issue":"3","key":"10.1016\/bs.apcsb.2021.11.002_bb0590","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"Cancer Journal for Clinicians"},{"issue":"10008","key":"10.1016\/bs.apcsb.2021.11.002_bb0595","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/S0140-6736(15)00239-1","article-title":"Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: A randomised, double-blind, placebo-controlled phase 2b trial","volume":"386","author":"Trimble","year":"2015","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/bs.apcsb.2021.11.002_bb0600","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00262-008-0596-0","article-title":"Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts","volume":"58","author":"Tseng","year":"2009","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"2","key":"10.1016\/bs.apcsb.2021.11.002_bb0605","doi-asserted-by":"crossref","first-page":"220","DOI":"10.18433\/J3RS3V","article-title":"Strategies for developing oral vaccines for human papillomavirus (HPV) induced cancer using nanoparticle mediated delivery system","volume":"18","author":"Uddin","year":"2015","journal-title":"Journal of Pharmacy & Pharmaceutical Sciences"},{"issue":"4","key":"10.1016\/bs.apcsb.2021.11.002_bb0610","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1158\/1078-0432.CCR-14-2142","article-title":"Vaccine-induced tumor necrosis factor\u2013producing T cells synergize with cisplatin to promote tumor cell death","volume":"21","author":"van der Sluis","year":"2015","journal-title":"Clinical Cancer Research"},{"issue":"12","key":"10.1016\/bs.apcsb.2021.11.002_bb0615","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s00262-016-1892-8","article-title":"Potential use of lymph node-derived HPV-specific T cells for adoptive cell therapy of cervical cancer","volume":"65","author":"van Poelgeest","year":"2016","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"10","key":"10.1016\/bs.apcsb.2021.11.002_bb0620","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1080\/14760584.2016.1176533","article-title":"Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: Hope or reality from clinical studies","volume":"15","author":"Vici","year":"2016","journal-title":"Expert Review of Vaccines"},{"issue":"1","key":"10.1016\/bs.apcsb.2021.11.002_bb0625","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1600-065X.2009.00765.x","article-title":"Immune regulation by 4-1BB and 4-1BBL: Complexities and challenges","volume":"229","author":"Wang","year":"2009","journal-title":"Immunological Reviews"},{"key":"10.1016\/bs.apcsb.2021.11.002_bb0630","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.canlet.2019.11.039","article-title":"Human papillomavirus vaccine against cervical cancer: Opportunity and challenge","volume":"471","author":"Wang","year":"2020","journal-title":"Cancer Letters"},{"issue":"1","key":"10.1016\/bs.apcsb.2021.11.002_bb0635","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-016-0293-9","article-title":"Perspectives for therapeutic HPV vaccine development","volume":"23","author":"Yang","year":"2016","journal-title":"Journal of Biomedical Science"},{"issue":"8","key":"10.1016\/bs.apcsb.2021.11.002_bb0640","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1586\/14760584.2016.1157477","article-title":"Current state in the development of candidate therapeutic HPV vaccines","volume":"15","author":"Yang","year":"2016","journal-title":"Expert Review of Vaccines"},{"issue":"8","key":"10.1016\/bs.apcsb.2021.11.002_bb0645","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/sj.mt.6300149","article-title":"Increased sensitivity of radiated murine cervical Cancer tumors to E7 subunit vaccine\u2013driven CTL-mediated killing induces synergistic anti-tumor activity","volume":"15","author":"Ye","year":"2007","journal-title":"Molecular Therapy"},{"key":"10.1016\/bs.apcsb.2021.11.002_bb0650","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.3389\/fimmu.2020.01012","article-title":"CD40 accelerates the antigen-specific stem-like memory CD8(+)T cells formation and human papilloma virus (HPV)-positive tumor eradication","volume":"11","author":"Zhang","year":"2020","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.apcsb.2021.11.002_bb0655","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.2147\/IJN.S291421","article-title":"Immunotherapy of tumor RNA-loaded lipid nanoparticles against hepatocellular carcinoma","volume":"16","author":"Zhang","year":"2021","journal-title":"International Journal of Nanomedicine"},{"issue":"9","key":"10.1016\/bs.apcsb.2021.11.002_bb0660","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.7314\/APJCP.2015.16.9.3843","article-title":"Immunotherapeutic effects of dendritic cells pulsed with a Coden-optimized HPV 16 E6 and E7 fusion gene in vivo and in vitro","volume":"16","author":"Zhou","year":"2015","journal-title":"Asian Pacific Journal of Cancer Prevention"},{"key":"10.1016\/bs.apcsb.2021.11.002_bb0665","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.3389\/fimmu.2020.01434","article-title":"Progress in vaccination of prophylactic human papillomavirus vaccine","volume":"11","author":"Zhou","year":"2020","journal-title":"Frontiers in Immunology"}],"container-title":["Advances in Protein Chemistry and Structural Biology","Immunotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876162321000833?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876162321000833?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T07:25:28Z","timestamp":1756193128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876162321000833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9780323992275"],"references-count":132,"URL":"https:\/\/doi.org\/10.1016\/bs.apcsb.2021.11.002","relation":{},"ISSN":["1876-1623"],"issn-type":[{"value":"1876-1623","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]}}}